Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro­deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transplantation


Authors: Z. Adam 1;  Z. Řehák 2;  R. Koukalová 2;  P. Szturz 1;  M. Krejčí 1;  L. Pour 1;  L. Zahradová 1;  M. Moulis 3;  R. Kodet 4;  T. Nebeský 5;  M. Brejcha 6;  Z. Adamová 7;  R. Hájek 1;  J. Mayer 1
Authors‘ workplace: Interní hematoonkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Mayer, CSc. 1;  Oddělení nukleární medicíny, centrum PET Masarykova onkologického ústavu Brno, přednosta prim. MUDr. Karol Bolčák 2;  Ústav patologie Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta doc. MUDr. Josef Feit, CSc. 3;  Ústav patologie a molekulární medicíny 2. lékařské fakulty UK a FN Motol Praha, přednosta prof. MUDr. Roman Kodet, CSc. 4;  Radiologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Vlastimil A. Válek, CSc. 5;  Hematologické oddělení Komplexního onkologického centra Nový Jičín, přednosta prim. MUDr. Martin Brejcha 6;  Chirurgické oddělení Nemocnice Vsetín, přednosta prim. MUDr. Jaroslav Sankot 7
Published in: Vnitř Lék 2012; 58(1): 62-71
Category: Case Reports

Overview

Adult Langerhans cell histiocytosis (LCH) usually follows a favorable course. Very rarely, however, multi-system (multi-organ) LCH difficult to manage either with traditional first line treatment (vinblastine, mercaptopurine, prednisone or etoposide) or 2-chlorodeoxyadenosine occurs. In these patients, other treatment modalities have to be used. We describe a patient with LCH manifesting with generalized lymphadenopathy and infiltrating the pulmonary parenchyma and skin. The disease activity was always associated with B-symptoms (weight loss, subfebrile states, night sweats). Histological investigations repeatedly showed higher proliferation activity than that usual in adult patients with LCH. Expression of Ki-67 proliferation marker was up to 30% and there were 8–10 cells in mitosis in the microscope viewing field. Therefore, therapy started with the application of stimulation regimen (cyclophosphamide 2 g/m2 on day 1 and etoposide 200 mg/m2 on days 1–3) followed by collection of peripheral blood stem cells. Then, treatment with 2-chlorodeoxyadenosine, the first 3 cycles as monotherapy of 5 mg/m2 SC on days 1–5 in 28-day cycles, the next 3 cycles in combination with cyclophosphamide 150 mg/m2 on days 1–5 and methylprednisolone 250 mg on days 1–5, was used. However, the disease relapsed 2 months after completion of the therapy. This early relapse was treated with 4 cycles of CHOEP chemotherapy (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone). Following the 4th cycle of CHOEP, high-dose BEAM chemotherapy (carmustine, etoposide, cytarabine, melphalan) with autologous stem cell transplantation were administered. According to the follow-up PET-CT examination, this treatment resulted in complete disease remission. However, the disease relapsed again in the lymph nodes, lungs, skin and bones 5 months after the high-dose chemotherapy. The progression was documented on PET-CT scanning. Lenalidomide 25 mg daily for 21 days in 28-day cycles with dexamethasone 20 mg once a week were administered as the 4th line treatment. After the 4th cycle of lenalidomide, PET-CT was performed, where the CT component suggested a significant reduction (more than 50%) in the size of the lymph nodes and the PET component showed substantial reduction in fluorodeoxyglucose accumulation in the affected lymph nodes as well as in the bone lesions. HRCT showed disappearance of pulmonary nodules. During the treatment, CRP levels declined and hemoglobin rose from 110 to 141 g/l, i.e. partial remission was achieved after 4 cycles. Etoposide (100 mg IV) was added to lenalidomide and dexamethasone on days 22, 23 and 24 of the above mentioned 28-day cycle. The added etoposide further intensified treatment response. In all, 11 cycles of this chemotherapy were given, resulting in complete remission confirmed by follow-up PET-CT. The achieved remission was consolidated using allogeneic bone marrow transplantation after FLAMSA reduced intensity conditioning without amsacrine. Four months after allogeneic transplantation, the patient has been relapse free. Herein we presented treatment response of highly aggressive LCH to lenalidomide. The used four cycles led to partial remission only and with the combination of lenalidomide, dexamethasone and etoposide the treatment response was further intensified to complete remission.

Key words:
Langerhans cell histiocytosis – lenalidomide – 2-chlorodeoxyadenosine – etoposide


Sources

1. Ščudla V, Roček V, Dušek B et al. Multifokální eozinofilní granulom v dospělosti. Vnitř Lék 1987; 33: 1078–1086.

2. Doberauer C. Langerhans cell histiocytosis in adults. Vnitř Lék 2010; 56 (Suppl 2): 22–26.

3. Fichter J, Doberauer C, Seegenschmiedt H. Langerhans cell histiocytosis in adults: An interdisciplinary challenge. Dtsch Arztebl 2007; 104: A2347–A2353.

4. Aricò M, Gischikovsky M, Généreau T et al. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer 2003; 39: 2341–2348.

5. Mottl H, Ganevová M, Radvanská J et al. Treatment results of Langerhans cell histiocytosis with LSH II protocol. Čas Lék Čes 2005; 144: 753–755.

6. Mottl H, Starý J, Chánová M et al. Treatment of recurrent Langerhans cell histiocytosis in children with 2-chlorodeoxyadenosine. Leuk Lymphoma 2006; 47: 1881–1884.

7. Teng CL, Lin TH, Young JH et al. Rapidly fatal Langerhans’ cell histiocytosis in an adult. J Formos Med Assoc 2005; 104: 955–659.

8. McClain KL. Drug therapy for the treatment of Langerhans cell histiocytosis. Expert Opin Pharmacother 2005; 6: 2435–2441.

9. Allen CE, McClain KL. Langerhans cell histiocytosis: a review of past, current and future therapies. Drugs Today 2007; 43: 627–643.

10. Saven A, Burian C. Cladribine activity in adult Langerhans-cell histiocytosis. Blood 1999; 93: 4125–4130.

11. Weitzman S, Wayne AS, Arceci R at al. Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the histiocyte society and review of the literature. Med Pediatr Oncol 1999; 33: 476–481.

12. Imamura T, Sato T, Shiota Y et al. Outcome of pediatric patients with Langerhans cell histio­cytosis treated with 2 chlorodeoxyadenosine: a nationwide survey in Japan. Int J Hematol 2010; 91: 646–651.

13. Weitzman S, Braier J, Donadieu J et al. 2’-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). Results of the LCH-S-98 protocol of the Histio­cyte Society. Pediatr Blood Cancer 2009; 53: 1271–1276.

14. Sander CS, Kaatz M, Elsner P. Successful treatment of cutaneous langerhans cell histiocytosis with thalidomide. Dermatology 2004; 208: 149–152.

15. Kolde G, Schulze P, Sterry W. Mixed response to thalidomide therapy in adults: two cases of multisystem Langerhans’ cell histiocytosis. Acta Derm Venereol 2002; 82: 384–386.

16. Claudon A, Dietemann JL, Hamman De Compte A et al. Interest in thalidomide in cutaneo-mucous and hypothalamo-hypophyseal involvement of Langerhans cell histiocytosis. Rev Med Interne 2002; 23: 651–656.

17. Lair G, Marie I, Cailleux N et al. Langerhans histiocytosis in adults: cutaneous and mucouslesion regression after treatment with thalidomide. Rev Med Interne 1998; 19: 196–198.

18. Dallafior S, Pugin P, Cerny T et al. Successful treatment of a case of cutaneous Langerhans cell granulomatosis with 2-chlorodeoxyadenosine and thalidomide. Hautarzt 1995; 46: 553–560.

19. Meunier L, Marck Y, Ribeyre C et al. Adult cutaneous Langerhans cell histiocytosis: remission with thalidomide treatment. Br J Dermatol 1995; 132: 168.

20. Thomas L, Ducros B, Secchi T et al. Successful treatment of adult’s Langerhans cell histiocytosis with thalidomide. Report of two cases and literature review. Arch Dermatol 1993; 129: 1261–1264.

21. Misery L, Larbre B, Lyonnet S et al. Remission of Langerhans cell histiocytosis with thalidomide treatment. Clin Exp Dermatol 1993; 18: 487–488.

22. Bensaid P, Machet L, Vaillant L et al. Langerhans-cell histiocytosis in the adult: regressive parotid involvement following thalidomide therapy. Ann Dermatol Venereol 1992; 119: 281–283.

23. Chen M, Doherty SD, Hsu S. Innovative uses of thalidomide. Dermatol Clin 2010; 28: 577–586.

24. Li R, Lin T, Gu H et al. Successful thalidomide treatment of adult solitary perianal Langerhans cell histiocytosis. Eur J Dermatol 2010; 20: 391–392.

25. Broekaert SM, Metzler G, Burgdorf W et al. Multisystem Langerhans cell histiocytosis: successful treatment with thalidomide. Am J Clin Dermatol 2007; 8: 311–314.

26. Alioua Z, Hjira N, Oumakhir S et al. Thalidomide in adult multisystem Langerhans cell histio­cytosis: a case report. Rev Med Interne 2006; 27: 633–636.

27. McClain KL, Kozinetz CA. A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer 2007; 48: 44–49.

28. Wu JJ, Huang DB, Pang KR et al. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol 2005; 153: 254–273.

29. Mauro E, Fraulini C, Rigolin GM et al. A case of disseminated Langerhans’ cell histiocytosis treated with thalidomide. Eur J Haematol 2005; 74: 172–174.

30. Crane E, List A. Immunomodulatory drugs. Cancer Invest 2005; 23: 625–634.

31. De Sanctis JB, Mijares M, Suárez A et al. Pharmacological properties of thalidomide and its analogues. Recent Pat Inflamm Allergy Drug Discov 2010; 4: 144–148.

32. Dreicer R. Lenalidomide: immunomodulatory, antiangiogenic, and clinical activity in solid tumors. Curr Oncol Rep 2007; 9: 120–123.

33. Knight R. IMiDs: a novel class of immunomodulators. Semin Oncol 2005; 32 (4 Suppl 5): S24–S30.

34. Kotla V, Goel S, Nischal S et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009; 2: 36–40.

35. Galustian C, Dalgleish A. Lenalidomide: a novel anticancer drug with multiple modalities. Expert Opin Pharmacother 2009; 10: 125–133.

36. Awan FT, Johnson AJ, Lapalombella R et al. Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 2010; 51: 27–38.

37. Fine HA, Kim L, Albert PS et al. A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Clin Cancer Res 2007; 13: 7101–7106.

38. Mandac I, Kolonic SO. Lenalidomide induced good clinical response in a patient with multiple relapsed and refractory Hodgkin’s lymphoma. J Hematol Oncol 2010; 3: 20–25.

39. Sher T, Miller KC, Lawrence D et al. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma 2010; 51: 85–88.

40. Böll B, Borchmann P, Topp MS et al. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol 2010; 148: 480–482.

41. Habermann TM, Lossos IS, Justice G et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009; 145: 344–349.

42. Tempescul A, Ianotto JC, Morel F et al. Lenalidomide, as a single agent, induces complete remission in a refractory mantle cell lymphoma. Ann Hematol 2009; 88: 921–922.

43. Wiernik PH, Lossos IS, Tuscano JM et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2008; 26: 4952–4957.

44. Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008; 26: 1544–1552.

45. Battoo SA, Hernandez-Ilizaliturri F. The emerging role of lenalidomide in the management of lymphoid malignancies. Ther Adv Hematom 2011; 2: 45–53.

46. Kudo K, Ohga S, Morimoto A et al. Improved outcome of refractory Langerhans cell histio­cytosis in children with hematopoietic stem cell transplantation in Japan. Bone Marrow Transplant 2010; 45: 901–906.

47. Caselli D, Aricò M. EBMT Paediatric Working Party. The role of BMT in childhood histiocytoses. Bone Marrow Transplant 2008; 41 (Suppl 2): S8–S13.

48. Kesik V, Citak C, Kismet E et al. Hemato­poietic stem cell transplantation in Langerhans cell histiocytosis: case report and review of the literature. Pediatr Transplant 2009; 13: 371–374.

49. Ingram W, Desai SR, Gibbs JS et al. Reduced-intensity conditioned allogeneic haematopoietic transplantation in an adult with Langerhans’ cell histiocytosis and thrombocytopenia with absent radii. Bone Marrow Transplant 2006; 37: 713–715.

50. Steiner M, Matthes-Martin S, Attarbaschi A et al. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2005; 36: 215–225.

51. Akkari V, Donadieu J, Piguet C et al. French Langerhans Cell Study Group. Hematopoietic stem cell transplantation in patients with severe Langerhans cell histiocytosis and hematological dysfunction: experience of the French Langerhans Cell Study Group. Bone Marrow Transplant 2003; 31: 1097–1103.

52. Adam Z, Řehák Z, Koukalová R et al.Plicní forma histiocytózy z Langerhansových buněk – hodnocení aktivity nemoci a léčebné odpovědi pomocí PET-CT (indexu SUVmax Pulmo/SUVmax Hepar). Popis vlastních zkušeností a přehled literatury. Vnitř Lék 2010; 56: 1228–1251.

Labels
Diabetology Endocrinology Internal medicine

Article was published in

Internal Medicine

Issue 1

2012 Issue 1

Most read in this issue

This topic is also in:


Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account